Amneal Pharmaceuticals (AMRX) Tops Q1 EPS by 5c, provides guidance

Amneal Pharmaceuticals (: AMRX) reported Q1 EPS of $0.14, $0.05 better than the analyst estimate of $0.09. Revenue for the quarter came in at $659 million versus the consensus estimate of $620.31 million.

GUIDANCE:

Amneal Pharmaceuticals sees FY2024 EPS of $0.53-$0.63, versus the consensus of $0.58. Amneal Pharmaceuticals sees FY2024 revenue of $2.55-2.65 billion, versus the consensus of $2.604 billion. Capital expenditures: $60 million - $70 million. Operating cash flow: $260 million - $300 million.

For earnings history and earnings-related data on Amneal Pharmaceuticals (AMRX) click here.

You May Also Be Interested In

• Macy's (M) Tops Q2 EPS by 28c, Beats on Revenue; Offers FY Guidance
• ABM Industries (ABM) Reports In-Line Q3 EPS; raises guidance
• Braze, Inc. (BRZE) Tops Q2 EPS by 4c; offers guidance